Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Treating CLL after venetoclax or BTK inhibitors

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines the treatment options for chronic lymphocytic leukemia (CLL) patients who relapse after venetoclax or BTK inhibitors. Dr Mazyar specifically discusses how later lines ought to be considered early, and also mentions potential strategies the future could hold, such as CAR-T. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.